Epic Sciences is a company.
Epic Sciences has raised $159.0M across 5 funding rounds.
Key people at Epic Sciences.
Epic Sciences has raised $159.0M in total across 5 funding rounds.
Epic Sciences has raised $159.0M in total across 5 funding rounds.
Epic Sciences's investors include Deerfield Management, Domain Associates, Foresite Capital.
Epic Sciences is a biotechnology company founded in 2008 that develops novel diagnostics to personalize and advance cancer treatment and management.[1][2][3] Its core mission is to enable rapid, non-invasive detection of genetic and molecular changes in cancer throughout a patient's journey, using a proprietary platform to identify and characterize rare cells like circulating tumor cells (CTCs).[1][2][3][4] The company serves physicians, patients, pharmaceutical partners (over 65), and major cancer centers (including 45 academic hospitals and the National Cancer Institute), solving the problem of matching patients to targeted therapies, monitoring drug resistance, and improving clinical trial success by providing real-time insights for treatment decisions.[2][3][4] With 51-200 employees headquartered in San Diego, Epic has demonstrated growth through a $52 million Series E financing in 2018, CAP accreditation, partnerships like Genomic Health for the Oncotype DX AR-V7 Nucleus Detect test for prostate cancer, involvement in over 200 clinical trials, and testing of more than 10,000 patient samples.[1][3][4][5]
Epic Sciences was established in 2008 in San Diego on a foundational platform for detecting rare cells, including CTCs, to address gaps in cancer diagnostics.[1][2][3][4] While specific founders are not detailed in available sources, the company has been led by CEO Lloyd Sanders (placed via executive search), with key executives including Chief Innovation Officer Ryan Dittamore, Chief Scientific Officer Pascal Bamford, Chief Commercial Officer Katherine Atkinson, and others in research, lab, and finance roles.[1] Early traction came from building "No Cell Left Behind®" technology, securing partnerships with pharma and cancer centers, and expanding its test pipeline for cancers like prostate, breast, lung, and bladder; pivotal moments include CAP accreditation, the 2018 Series E funding, and commercialization efforts like the AR-V7 test with Genomic Health.[3][4][5]
Epic Sciences stands out in oncology diagnostics through these key strengths:
Epic Sciences rides the wave of precision oncology and liquid biopsy trends, where non-invasive blood tests replace invasive biopsies to track cancer dynamics in real time.[2][3][4] Timing aligns with surging demand for personalized medicine amid rising cancer prevalence and immunotherapy advancements, as market forces like high clinical trial failure rates (favoring Epic's success-boosting tools) and payer pressures for cost-effective treatments propel adoption.[3][4] By partnering globally and influencing 200+ trials, Epic shapes the ecosystem, accelerating drug approvals, reducing ineffective therapies, and enabling pharma to optimize trials while empowering physicians with data-driven decisions.[2][4]
Epic Sciences is poised to expand its diagnostic pipeline and market presence, leveraging its platform for new tests in high-impact cancers and combination therapies amid AI-enhanced biotech integration.[2][3][4] Trends like multimodal liquid biopsies and immune monitoring will shape its path, potentially driving acquisitions or IPOs as oncology spending hits new highs. Its influence could grow by dominating predictive testing, tying back to its mission of transforming patient journeys through certainty in pivotal decisions.[1][3]
Key people at Epic Sciences.
Epic Sciences has raised $159.0M across 5 funding rounds. Most recently, it raised $24.0M Series G in April 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2023 | $24.0M Series G | Deerfield Management, Domain Associates, Foresite Capital | |
| Sep 1, 2018 | $52.0M Series E | Deerfield Management, Domain Associates | |
| Apr 1, 2017 | $40.0M Series D | Deerfield Management, Domain Associates | |
| Jul 1, 2014 | $30.0M Series C | Deerfield Management, Domain Associates | |
| Nov 1, 2012 | $13.0M Series B | Deerfield Management, Domain Associates |
